Mackenzie Financial’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-4,060
Closed -$614K 1629
2022
Q3
$614K Sell
4,060
-193
-5% -$28.6K ﹤0.01% 892
2022
Q2
$620K Sell
4,253
-18,855
-82% -$2.41M ﹤0.01% 925
2022
Q1
$2.74M Buy
23,108
+19,920
+625% +$2.48M ﹤0.01% 694
2021
Q4
$439K Buy
3,188
+26
+0.8% +$3.31K ﹤0.01% 1021
2021
Q3
$439K Buy
+3,162
New +$395K ﹤0.01% 1016

Other funds holding BHVN

Mackenzie Financial's BHVN Position: Q4 2022 in Review

Mackenzie Financial sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 4,060 shares — an estimated $614K sold.

Mackenzie Financial first reported a position in BHVN in Q3 2021 and held it in 5 quarters. The position peaked at $2.74M in Q1 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Mackenzie Financial reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Mackenzie Financial sold 4,060 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $614K.
  • Mackenzie Financial first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021 and held it in 5 quarters.
  • Mackenzie Financial's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2.74M in Q1 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Mackenzie Financial's 13F filing for Q4 2022, filed 14 Feb 2023.